Search En menu ClientConnect
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages

    Signature(s)

    Amount
    € 30,000,000
    Countries
    Sector(s)
    United Kingdom : € 30,000,000
    Industry : € 30,000,000
    Signature date(s)
    13/09/2013 : € 30,000,000

    Summary sheet

    Release date
    6 January 2014
    Status
    Reference
    Signed | 13/09/2013
    20110333
    Project name
    Promoter - financial intermediary
    Norgine R&D Facility
    Norgine BV
    Proposed EIB finance (Approximate amount)
    Total cost (Approximate amount)
    EUR 30 million
    EUR 137 million
    Location
    Sector(s)
    Description
    Objectives

    The project concerns the promoter’s European based R&D activities, in the fields of gastroenterology and pain management. The promoter has a very healthy late stage product pipeline (five products in phase III and only two in phase I). The evaluation of this pipeline and the promoter’s strategy for its development will be a key part of the appraisal.

    Financing of Norgine's pharmaceutical research and development from 2012 to 2014.

    Environmental aspects
    Procurement

    The activities are monitored by the company’s internal control department, to verify compliance with the ISO 14000 standards on environmental management. Competent national authorities and the European Medical Agency (EMEA) frequently inspect the sites concerned by the project to check compliance with the relevant environmental and health regulations.

    The promoter is a private company, not operating in the Utilities sector and therefore not covered by EU Directives on procurement. Procedures followed are expected to be in the best interest of the project and satisfactory to the Bank. This will be verified during appraisal.

    Comments

    The Risk Sharing Finance Facility (RSFF) is an innovative credit risk sharing scheme jointly set up by the European Commission and the European Investment Bank to improve access to debt financing for private companies or public institutions promoting activities with a higher financial risk profile in the fields of research, technological development, demonstration and innovation investments.

    Disclaimer

    Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).

    Documents

    Environmental and Social Data Sheet (ESDS) - NORGINE R&D FACILITY
    Publication Date
    2 Feb 2016
    Document language
    Main Topic
    Lending
    Document Number
    64481220
    Document Focus
    Environmental Information
    Project Number
    20110333
    Sector(s)
    Regions
    Countries
    Publicly available
    Download now

    General enquiries and comments

    The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
    Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
    Alternatively, the EIB can be contacted through its external offices.
    Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

    Media enquiries

    Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

    Complaints mechanism

    Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

    Zero tolerance against fraud and corruption

    The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.

    Related publications